North America Immunoglobulin Market 2022-2028
MARKET OUTLOOK
According to Triton’s research report, immunoglobulin in North America is likely to grow with a CAGR of 6.85% over the projected duration from 2022 to 2028. Canada and the United States are the countries included in the market in this region.
Due to the increased risk of various diseases in the United States and Canada, the immunoglobulin market in the North American region is growing. The high prevalence of various diseases among people in the US and rising FDA approvals are some of the key elements anticipated to support the expansion of the immunoglobulin market in the country throughout the forecast period.
Furthermore, it is anticipated that an increase in product approvals by the US Food and Drug Administration will increase the demand and adoption of immunoglobulin products in the region. The United States has a number of well-known industry players, which opens up opportunities for technological and product development advances in the field of immunoglobulins.
During the projected period, the rising prevalence of diseases is one of the key factors anticipated to support the growth of the immunoglobulin market in Canada. Additionally, there has been a large expansion of the immunoglobulin and plasma infrastructure across Canada recently, which is anticipated to have a favorable effect on the market’s expansion over the years to come.
COMPETITIVE OUTLOOK
Grifols SA, Takeda Pharmaceutical Company Limited, ADMA Biologics, LFB Group, Kamada Ltd, Octapharma AG, Sanquin Plasma Products BV, Bio Products Laboratory, and CSL Behring are some of the biggest names in the immunoglobulin market.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook